Aim: To evaluate the prognostic value of plasma big endothelin-1 level in the context of three-vessel disease (TVD) with heavy atherosclerotic burden.
Declaration of Helsinki and was approved by the Review Board of Fuwai Hospital. Written informed consent was obtained from all participants.
Definitions
The concentrations of plasma big ET-1 were measured in fasting venous blood samples after admission for coronary angiography, using a highly sensitive and specific commercial sandwich enzyme immunoassay (BI-20082H; Biomedica, Wien, Austria). The SS was calculated using an online calculator (http://www.syntaxscore.com) by a dedicated research group blinded to the clinical data. Calculation of the SS was based on two anatomical variables and six clinical variables 3) . Creatinine clearance was calculated by the Cockcroft and Gault formula.
Outcomes
Outcome data were obtained by telephone interview, follow-up letter or clinic visit. All events were carefully checked and verified by an independent group of clinical physicians. Investigator training, blinded questionnaire filling, and telephone recording were performed to achieve high-quality results. The primary endpoint was all-cause death. Secondary endpoints included cardiac death, major adverse cardiac and cerebrovascular events (MACCE), a composite of all-cause death, MI, stroke, or unplanned revascularization, and the individual components of the composite. All deaths were considered cardiac unless an unequivocal noncardiac cause could be established.
Statistical Analysis
A receiver operating characteristic (ROC) curve analysis was performed to determine the optimal cutoff value of plasma big ET-1 for mortality prediction (Supplementary Fig.1 ). Participants were divided into high and low big ET-1 groups according to this cutoff value.
Summary statistics were presented as frequency and percentage for categorical variables and mean standard deviation or median and interquartile range for continuous variables. An independent-sample Student's t -test or the Mann -Whitney U -test was performed for comparisons of continuous variables, and the Pearson chi-square test or Fisher's exact test was performed for comparison of categorical variables.
Survival curves were constructed by the Kaplan -Meier method and compared by the log-rank test. Univariable and multivariable Cox proportional hazards regressions were performed to calculate the hazard ratio (HR) and 95% confidence interval (CI) and evaluate the associations between big ET-1 level (as a categorical or continuous variable normalized by log10 low-up. With this aim, the SYNTAX score (SS) and SYNTAX score (SS ) have been established for risk assessment in patients with TVD 2, 3) . However, accurate risk stratification has always been challenging. Identification of additional biomarkers with prognostic significance may be able to improve the predictability of the established models.
Endothelin-1 (ET-1), a 21-amino acid peptide, is the most powerful constrictor of human vessels discovered to date 4) . It is primarily produced and released by vascular endothelial cells and can cause endothelial dysfunction and inflammation, which may contribute to atherosclerotic plaque formation 5) . However, clinical use of ET-1 as a biomarker is limited because of its instability in plasma 6) . As a precursor of ET-1, big ET-1 is relatively stable and can be used as an alternative approach for indirect estimation of ET-1 release 6) . Big ET-1 level was shown to be correlated with disease severity and clinical outcome in patients with acute myocardial infarction (MI) and stable CAD [7] [8] [9] [10] . However, its clinical implications have not been evaluated in the setting of TVD with advanced coronary atheroma burden.
Aim
The present study aimed to assess the prognostic value of plasma big ET-1 level in patients with TVD.
Methods

Study Design and Participants
Data were obtained from a large prospective cohort study in which a total of 8,943 patients with TVD were consecutively enrolled from April 2004 to February 2011 at Fuwai Hospital, Chinese Academy of Medical Sciences (Beijing, China). Eligible patients were those who had TVD, defined as angiographically confirmed stenosis of ≥ 50% in all three main epicardial coronary arteries (left anterior descending, left circumflex, and right coronary arteries) with or without involvement of the left main artery, and were willing to undergo follow-up. There were no prespecified exclusion criteria. No treatment intervention was dictated by the protocol for the observational study. Patients received medical therapy (MT) alone, percutaneous coronary intervention (PCI), or coronary artery bypass grafting (CABG) according to contemporary practice guidelines and their preferences 11, 12) . After enrollment, the patients were followed up in accordance with the study protocol. Baseline and procedural data for all participants were collected into a database by independent clinical research coordinators.
The study complied with the principles of the calculated using R software version 3.4.3 (R Core Team, Vienna, Austria). Two-sided P-values of 0.05 were considered statistically significant. Analyses were performed using SPSS software version 22.0 (IBM, Armonk, NY, USA) unless otherwise stated.
Results
A total of 6,150 patients with available big ET-1 data were included in the present analysis. On the basis of the optimal cutoff value of 0.79 pmol/L, the patients were divided into low and high big ET-1 groups ( Fig. 1) . At baseline, patients in the high big ET-1 group were older and had higher troponin I, N-terminal pro-Btype natriuretic peptide, and high-sensitivity C-reactive protein, but lower LVEF and creatinine clearance ( Table 1) . Higher rates of female sex, hypertension, diabetes, previous MI, previous stroke, chronic kidney disease, and high SS were observed in the high big ET-1 group. Patients in the high big ET-1 group were more likely to receive MT alone rather than CABG and to take aspirin.
The median follow-up was 6.8 (5.7 -8.1) years, with a response rate of 82.0% (Fig. 1) . The baseline transformation) and clinical outcomes. Covariates included in the multivariable model were age, sex, body mass index, hypertension, diabetes, previous MI, previous stroke, clinical presentation (stable angina pectoris [SAP] or acute coronary syndrome [ACS]), left main coronary artery involvement, left ventricular ejection fraction (LVEF), creatinine clearance, SS ( ≤ 22, 23 -32, or ≥ 33), procedure (MT, PCI, or CABG), and aspirin. Patients who were lost to follow-up were censored at the last available contact.
Exploratory subgroup analyses of the primary outcome were performed according to age ( 65 or ≥ 65 years), sex (male or female), diabetes (yes or no), presentation (SAP or ACS), left main involvement (yes or no), LVEF ( 40% or ≥ 40%), SS (0 -22, 23 -32, or ≥ 33), and procedure (MT, PCI, or CABG). Interactions between plasma big ET-1 level (high or low) and these covariates were tested to interpret potential subgroup differences. The above-described multivariable Cox proportional hazards models were used for the interaction and subgroup analyses.
To assess the added prognostic value of big ET-1 for mortality prediction beyond the SS , the C-index, continuous net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were follow-up. During the follow-up period, 818 (13.3%) patients experienced all-cause death. The median level of plasma big ET-1 was significantly higher in the characteristics of the patients followed up and lost to follow-up are listed in Supplementary Table 1 . All patients included in the analysis completed at least one Table 3 ).
Discussion
The study shows that (i) high plasma big ET-1 level is an independent risk factor for all-cause death, cardiac death, and MACCE and is relatively consistent across subgroups and (ii) plasma big ET-1 level improves predictability of the SS for long-term mortality in patients with TVD.
Plasma big ET-1 level has been identified as a novel marker of disease severity and clinical outcome in the context of CAD. Big ET-1 level was a predictor of severity in stable CAD, as reflected by the Gensini score 9) . Moreover, two cohort studies found that high big ET-1 level was associated with increased risks of adverse outcomes in patients with stable CAD 8, 10) . In another cohort study of 983 patients with acute MI, patients who died (0.74 [0.54 -1.08] pmol/L) than in those who survived (0.64 [0.50 -0.84] pmol/L, P 0.001). Significantly more all-cause death, cardiac death, MACCE, and stroke occurred in the high big ET-1 group compared with the low big ET-1 group (all P 0.05, Table 2 ).
Univariable analysis showed that high big ET-1 level was associated with higher risks of all-cause death, cardiac death, and MACCE, but not MI, stroke, or unplanned revascularization ( Table 2) . After adjustment for covariates, high big ET-1 level remained an independent risk factor for all-cause death (HR: 1.36, 95% CI: 1.18 -1.57, P 0.001), cardiac death (HR: 1.36, 95% CI: 1.12 -1.66, P 0.002), and MACCE (HR: 1.19, 95% CI: 1.08 -1.31, P 0.001). Fig. 2 shows the Kaplan -Meier estimates for the primary and secondary endpoints (log-rank P 0.001 for all-cause death, cardiac death, and MACCE).
The relationship of big ET-1 level (high or low) with all-cause death was relatively consistent across the subgroups of age, sex, diabetes, presentation, left main disease, LVEF, SS, and procedure (Fig. 3) . There were no significant interactions between big ET-1 levels and these covariates (interaction P 0.1 for all subgroups). ment. Thus, high big ET-1 level remained an independent risk marker for mortality regardless of whether or not revascularization was performed.
ET-1 contributes to the poor prognosis in TVD patients through several mechanisms. First, as a vasoconstrictor, ET-1 accounts for nearly all the resting tone in atherosclerotic coronary arteries 14) . High ET-1 level can lead to vasoconstriction and decreased coronary blood flow, which may induce or aggravate myocardial ischemia. Second, ET-1 can decrease nitric oxide (NO) production and increase NO degradation, leading to an imbalance between NO and ET-1 and subsequent endothelial dysfunction in the coronary circulation 15) . Third, ET-1 can promote increases in oxidative stress and inflammatory cell infiltration, which contribute to atherosclerotic plaque formation, progression, and rupture 16) . These effects can be even more big ET-1 level was an independent predictor of death or heart failure, with an area under the ROC curve of 0.76 7) . These studies demonstrated that higher level of big ET-1 was associated with higher risks of adverse events in stable CAD or ACS, in accordance with the present study performed in SAP and ACS patients. The present study further extended the association to the setting of TVD with heavy atherosclerotic burden.
Revascularization (PCI or CABG) has been considered to improve prognosis in patients with multivessel disease compared with MT alone 13) . It remains unknown whether there is an interaction between treatment (MT, PCI, or CABG) and big ET-1 level with outcomes. In our study, the association between big ET-1 level and mortality was relatively consistent across patients receiving MT, PCI, and CABG, with no significant interaction between big ET-1 level and treat- ers have been shown to provide additional prognostic information beyond clinical characteristics in CAD 24) . Addition of biomarkers to the SS may enhance its predictability, because it is mainly based on clinical characteristics. Our study demonstrated significant improvements in the C-index, NRI, and IDI after incorporation of big ET-1 level into the SS , indicating better predictive performance compared with the SS alone. These findings are of great importance because better risk stratification can be achieved for guidance of treatment. Furthermore, similar to the traditional biomarkers, measurement of plasma big ET-1 is simple and economic using a commercial immunoassay. Although more evidence is needed regarding the prognostic value of big ET-1 level, our study has shown the feasibility of its addition to the established model to improve predictability.
There are some limitations that should be noticed in this study. First, this was an observational study that significant and more likely to lead to adverse events in the setting of TVD with heavy atherosclerotic burden in all three major vessels. Compared with traditional biomarkers representing myocardial injury (troponin I), cardiac stress (N-terminal pro-B-type natriuretic peptide), and inflammation (high-sensitivity C-reactive protein), big ET-1 can reflect endothelial function that is important for the development of atherosclerosis 4) .
TVD is present in 20% -30% of patients with obstructive CAD 17, 18) . As a severe type of CAD, it confers an almost two-fold higher risk of mortality compared with single-vessel disease 1) . Calculation of the SS is recommended for assessment of the long-term mortality risk in TVD patients 19) but showed only modest predictability in previous studies 20, 21) . Despite the generally better performance of the SS compared with the SS, some studies found only a moderate discrimination ability of the SS for long-term mortality prediction in patients with multivessel disease 22, 23) . Biomark- HRs and 95% CIs were calculated by reference to the low big ET-1 group. The interaction between big ET-1 level and each covariate was tested by a multivariable Cox proportional hazards regression model. may suffer from potential selection and measurement biases. Second, all participants in the study were enrolled from a single specialized center for cardiovascular disease, which may limit the reliability and generalizability of our findings. Third, angiographic criteria were used as the main indications for revascularization, and physiological tests were only performed when a treatment decision could not be made using the angiographic findings alone. As a result, most of the participants in our study did not undergo preprocedural/ intraprocedural ischemia evaluations. Fourth, the present analyses were based on a single plasma big ET-1 measurement, and thus, potential fluctuations in its levels remain uncountable.
Conclusions
In patients with TVD, plasma big ET-1 level was significantly higher in patients who died during follow-up than those who survived. Higher big ET-1 level was independently associated with increased risks of all-cause death, cardiac death, and MACCE. Big ET-1 level improves the discrimination and reclassification of the SS to predict long-term mortality. Values are presented as mean standard deviation, median (interquartile) or number (%). ACEI, angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARB, angiotensin receptor blockers; BMI, body mass index; CABG, coronary artery bypass grafting; CCB, calcium channel blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; ET-1, endothelin-1; hsCRP, high sensitivity C reactive protein; LVEF, left ventricular ejection fraction; MI, myocardial infarction; MT, medical therapy; NT-proBNP, N-terminal pro-B-Type natriuretic peptide; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SAP, stable angina pectoris.
